KMDA — Kamada Ltd.

Is KMDA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Overbought As of November 17, 2026

Kamada Ltd. (KMDA) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $8.11. The rating moved from Neutral to Overbought on November 10, 2026.

See all overbought Healthcare stocks →

AI analysis

Kamada Ltd. (KMDA) is a small‑cap specialty biologics company with a revenue base tied to plasma‑derived products and upside optionality from development-stage assets. Short-term market tone is cautious but not distressed, which should limit extreme moves absent company‑specific news. Key strengths include recurring revenues from established products and potential upside from pipeline catalysts or strategic partnerships. Primary concerns are typical small‑cap biotech risks: regulatory outcomes, reimbursement pressure, limited near‑term financial visibility and potential dilution if capital is needed. Near‑term performance will hinge on disclosure of clinical/regulatory milestones, commercial traction in key markets, and any funding or licensing developments.

Key factors

  • Specialty biologics focus with established plasma‑derived product franchise that provides recurring revenue streams
  • Limited recent public financial disclosure in the provided window; historical revenue visibility from legacy products offsets development risk to some extent
  • Defensive healthcare flows into larger-cap pharma create a mixed readthrough for small-cap specialty biotechs—may reduce downside volatility but not materially increase capital access
  • Pipeline and potential new product launches represent growth optionality; outcomes-driven catalysts (approvals, commercialization agreements) could re-rate the stock
  • Relative valuation and equity liquidity (small-cap profile) can attract idiosyncratic moves and M&A interest given sector consolidation dynamics
  • Macroeconomic backdrop: cautious risk-on tone and low short-term volatility supports measured trading rather than aggressive deleveraging

Risks

  • Clinical or regulatory setbacks for pipeline assets or manufacturing quality issues for plasma‑derived products
  • Reimbursement and pricing pressure in key markets, especially for specialty treatments and orphan indications
  • Limited near‑term visibility on financials and operating cashflow may necessitate equity raises or partnership deals, diluting shareholders
  • Competition from larger diversified pharma and emerging biologics/GLP‑1 related shifts that could redirect payer and provider focus
  • Antitrust/regulatory environment in healthcare and distribution channels could change commercial dynamics for specialty distributors and partners
  • Low social/research coverage increases information asymmetry and can exacerbate volatility on company‑specific news

See today's live rating, score and targets

Members see the live hourly rating for KMDA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.